Ebola Update: More Experimental Treatments, Health Workers at Risk

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

Aug 23, 2018
Catherine Offord

Health workers in Democratic Republic of Congo have begun giving patients two experimental treatments to tackle the latest outbreak of Ebola as the number of cases climbs above 100, Reuters reports. The first dose of Gilead Science’s antiviral drug Remdesivir was administered on Tuesday (August 21), while the monoclonal antibody treatment mAb114 was deployed nearly two weeks ago. 

“As of 20 August 2018, a total of 102 confirmed and probable [Ebola virus disease] cases, including 59 deaths, have been reported,” the World Health Organization (WHO) writes in a situation report published yesterday (August 22). Besides mAb114, “The Ethics Committee in the Democratic Republic of the Congo has approved the use of four additional experimental therapeutics, namely: ZMapp, Remdesivir, Favipiravir, and Regn3450 - 3471 – 3479” to be used by Ebola treatment centers.

See “Q&A: Anthony Fauci Describes an Experimental Ebola Treatment

The latest outbreak was discovered at the beginning of August near Beni, a city in the eastern part of the country that is currently experiencing militia violence—an obstacle to the work of health authorities trying to contain the virus. “We don’t know if we are having all transmission chains identified,” WHO spokesman Tarik Jasarevic said during a news briefing in Geneva, Reuters reported last week (August 17). “The worst-case scenario is that we have these security blindspots where the epidemic could take hold that we don’t know about.”

See “New Ebola Outbreak in Democratic Republic of Congo

Health workers have been particularly affected by the latest outbreak, accounting for 12 of the 75 cases that have been confirmed so far. “There’s an extremely low level of knowledge and awareness about Ebola in the area,” epidemiologist Peter Salama, head of the WHO’s response to the outbreak, tells Science. “Early on, the health care workers took no precautions whatsoever, and unfortunately, we’re expecting more confirmed cases from that group.”

Meanwhile, vaccination teams are continuing to administer an experimental Ebola vaccine, Merck’s rVSV-ZEBOV, to health workers and people in contact with Ebola patients. Reuters reports that 2,179 people have received the vaccine so far, and more doses are on their way to Beni now.

See “Experimental Ebola Vaccinations to Resume in Democratic Republic of Congo

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.